ReviewFrontiers in oncology2022
Narrative Review of High-Dose-Rate Interstitial Brachytherapy in Primary or Secondary Liver Tumors.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Gut Microbiota Dysbiosis MediatesImmunity, inflammation and disease · 2026Article
- Cross-Cancer Circulating Proteins for the Prognosis of Primary and Metastatic Liver Cancer Treated with Local Ablation: Post Hoc Exploratory Analysis of the ESTIMATE Trial.Radiology. Imaging cancer · 2026Article
- Comparative analysis of target volume coverage and liver exposure in high-dose-rate interstitial brachytherapy andClinical and translational radiation oncology · 2026Article
- The Role of High-Dose-Rate Brachytherapy (Interventional Radiotherapy) in the Reirradiation of Liver Metastases.Cancers · 2025Article
- Article
- Computed tomography guided high dose rate brachytherapy for induced oligoprogression of colorectal cancer liver metastases.Scientific reports · 2025Article
- Comparison of interstitial high-dose-rate brachytherapy and stereotactic radiotherapy in breath-hold technique for inoperable primary and secondary liver tumors.Physics and imaging in radiation oncology · 2025Article
- EORTC/ESTRO defined induced oligopersistence of liver metastases from colorectal cancer - outcomes and toxicity profile of computer tomography guided high-dose-rate brachytherapy.Clinical & experimental metastasis · 2025Article
- Comprehensive cohort study: computer tomography-guided high-dose rate brachytherapy as metastasis-directed therapy for liver metastases from colorectal cancer in repeat oligoprogression.La Radiologia medica · 2025Article
- Diaphragm and lung dose in liver high-dose-rate interstitial brachytherapy: A dosimetry and toxicity report.Journal of contemporary brachytherapy · 2025Article
- The role of brachytherapy in liver metastases from colorectal cancer.Frontiers in immunology · 2025Article
- HDR brachytherapy versus robotic-based and linac-based stereotactic ablative body radiotherapy in the treatment of liver metastases - A dosimetric comparison study of three radioablative techniques.Clinical and translational radiation oncology · 2024Article
- Radiotherapy as a metastasis directed therapy for liver oligometastases - comparative analysis between CT-guided interstitial HDR brachytherapy and two SBRT modalities performed on double-layer and single layer LINACs.Frontiers in oncology · 2024Article
- Novel combination of GammaTile cesium-131 brachytherapy with 5-aminolevulinic acid fluorescence-guided resection in the re-irradiation of pediatric recurrent high-grade glioma: illustrative case.Journal of neurosurgery. Case lessons · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optimal management of intrahepatic malignancies involves a multidisciplinary approach. Although surgical resection has been considered the only curative approach, the use of several minimally invasive ablative techniques has dramatically increased the last two decades, mainly due to the fact that they provide similar oncological results with significantly decreased morbidity. Among these modalities, interstitial liver brachytherapy, probably the most flexible liver ablative method, with excellent clinical data on its safety and effectiveness, is frequently not even mentioned as an option in the current peer reviewed literature and guidelines. Brachytherapy is a type of radiotherapy utilizing radionuclides that are directly inserted into the tumor. Compared to external beam radiation therapy, brachytherapy has the potential to deliver an ablative radiation dose over a short period of time, with the advantage of a rapid dose fall-off, that allows for sparing of adjacent healthy tissue. For numerous malignancies such as skin, gynecological, breast, prostate, head and neck, bladder, liver and soft-tissue tumors, brachytherapy as a monotherapy or combined with external beam radiation therapy, has become a standard treatment for many decades. This review article aims to describe the high-dose-rate liver brachytherapy technique, its selection criteria, present its advantages and disadvantages, as well as the available clinical data, in order to help physicians to explore and hopefully introduce liver brachytherapy into their clinical routine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.